Literature DB >> 19154902

Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.

Yuji Tachimori1, Norio Kanamori, Norihisa Uemura, Norikazu Hokamura, Hiroyasu Igaki, Hoichi Kato.   

Abstract

OBJECTIVE: Chemoradiotherapy is a popular definitive therapy for esophageal carcinoma among many patients and oncologists. Although the complete response rates are high and short-term survival is favorable after chemoradiotherapy, persistent or recurrent locoregional disease is frequent. Salvage surgery is the sole curative intent treatment option for this course of the disease. The present study evaluates the safety and value of salvage esophagectomy for locoregional failure after high-dose definitive chemoradiotherapy for esophageal squamous cell carcinoma.
METHODS: We reviewed 59 consecutive patients with thoracic esophageal squamous cell carcinoma who underwent salvage esophagectomy after definitive chemoradiotherapy. All patients received more than 60 Gy of radiation plus concurrent chemotherapy for curative intent. The data were compared with those of patients who received esophagectomy without preoperative therapy.
RESULTS: Postoperative morbidity and mortality rates were increased among patients who underwent salvage esophagectomy compared with those who underwent esophagectomy without preoperative therapy (mean hospital stay, 38 vs 33 days; anastomotic leak rates, 31% vs 25%; respiratory complication rates, 31% vs 20%; reintubation within 1 week, 2% vs 2%; hospital mortality rates, 8% vs 2%). Tracheobronchial necrosis and gastric conduit necrosis were highly lethal complications after salvage esophagectomy; 3-year postoperative survivals were 38% and 58%, respectively.
CONCLUSION: Patients who underwent salvage esophagectomy after definitive high-dose chemoradiotherapy had increased morbidity and mortality. Nevertheless, this is acceptable in view of the potential long-term survival after salvage esophagectomy. Such treatment should be considered for carefully selected patients at specialized centers.

Entities:  

Mesh:

Year:  2009        PMID: 19154902     DOI: 10.1016/j.jtcvs.2008.05.016

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  61 in total

1.  Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.

Authors:  Tatsunori Minamide; Yusuke Yoda; Keisuke Hori; Kensuke Shinmura; Yasuhiro Oono; Hiroaki Ikematsu; Tomonori Yano
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

2.  Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy.

Authors:  Hiroya Takeuchi; Yoshiro Saikawa; Takashi Oyama; Soji Ozawa; Koichi Suda; Norihito Wada; Tsunehiro Takahashi; Rieko Nakamura; Naoyuki Shigematsu; Nobutoshi Ando; Masaki Kitajima; Yuko Kitagawa
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

3.  Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy.

Authors:  Masaru Morita; Ryuichi Kumashiro; Yuichi Hisamatsu; Ryota Nakanishi; Akinori Egashira; Hiroshi Saeki; Eiji Oki; Takefumi Ohga; Yoshihiro Kakeji; Shunichi Tsujitani; Takeharu Yamanaka; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2011-08-05       Impact factor: 7.527

Review 4.  Photodynamic therapy for esophageal cancer.

Authors:  Tomonori Yano; Ken Hatogai; Hiroyuki Morimoto; Yusuke Yoda; Kazuhiro Kaneko
Journal:  Ann Transl Med       Date:  2014-03

5.  Emergency oesophagectomy for oesophageal perforation after chemoradiotherapy for oesophageal cancer.

Authors:  M Schweigert; N Solymosi; A Dubecz; M Posada Gonzalez; R J Stadlhuber; D Ofner; H J Stein
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

6.  SAGES Technology and Value Assessment Committee safety and effectiveness analysis on immunofluorescence in the operating room for biliary visualization and perfusion assessment.

Authors:  Bryan J Sandler; Danny Sherwinter; Lucian Panait; Richard Parent; Jennifer Schwartz; David Renton
Journal:  Surg Endosc       Date:  2017-06-22       Impact factor: 4.584

7.  Risk factors for pulmonary complications after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Masayuki Watanabe; Yoshifumi Baba; Shiro Iwagami; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yuji Miyamoto; Nobuyuki Ozaki; Hideo Baba
Journal:  Surg Today       Date:  2013-04-14       Impact factor: 2.549

8.  Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.

Authors:  Yuji Akiyama; Takeshi Iwaya; Fumitaka Endo; Takehiro Chiba; Takeshi Takahara; Koki Otsuka; Hiroyuki Nitta; Keisuke Koeda; Masaru Mizuno; Yusuke Kimura; Akira Sasaki
Journal:  Surg Endosc       Date:  2017-06-29       Impact factor: 4.584

9.  Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Yoshifumi Baba; Masayuki Watanabe; Satoshi Ida; Takatsugu Ishimoto; Ryuichi Karashima; Shiro Iwagami; Yu Imamura; Yasuo Sakamoto; Yuji Miyamoto; Hideo Baba
Journal:  Surg Today       Date:  2014-07-06       Impact factor: 2.549

10.  Hyperglycemia 3 days after esophageal cancer surgery is associated with an increased risk of postoperative infection.

Authors:  Naoko Ito; Takeshi Iwaya; Kenichiro Ikeda; Yusuke Kimura; Yuji Akiyama; Masafumi Konosu; Kaoru Ishida; Hisataka Fujiwara; Koki Otsuka; Hiroyuki Nitta; Masahiro Kashiwaba; Keisuke Koeda; Satoshi Nishizuka; Masaru Mizuno; Akira Sasaki; Go Wakabayashi
Journal:  J Gastrointest Surg       Date:  2014-07-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.